| ACT | artemisinin combination therapy |
| ALLN | N-acetyl-L-leucyl-L-norleucinal |
| AQ | amodiaquine |
| ART | artemisinin |
| ARTR/S | artemisinin resistant/sensitive |
| ATM | artemether |
| ATS | artesunate |
| BiPY | 2,2′-bipyridyl |
| DCP | delayed clearance phenotype |
| DFO | Deferoxamine |
| DFP | Deferiprone |
| DHA | Dihydroartemisinin |
| DV | digestive vacuole |
| EPR | electron paramagnetic resonance |
| ER | endoplasmic reticulum |
| FPIX | ferriprotoporphyrin IX heme |
| ggcs, | gamma glutamylcysteine synthetase |
| GSH | glutathione |
| GSSG | glutathione disulfide |
| GWAS | genome-wide association study |
| Hb | hemoglobin |
| Hz | hemozoin |
| IC50 | half-maximal inhibitory concentration |
| iRBC | infected red blood cell |
| LD50 | half-maximal lethal concentration |
| LF | lumefantrine |
| MOA | mechanism of action |
| MQ | mefloquine |
| MRP | multidrug resistance protein |
| MS | mass spectrometry |
| PfPI3K | Plasmodium falciparum phosphatidyl-3′-kinase |
| PPQ | piperaquine |
| RSA | ring stage assay |
| SDS-PAGE | sodium dodecyl sulfate-polyacrylamide gel electrophoresis |
| SEA | Southeast Asia |
| SNP | single nucleotide polymorphism |
| QTL | quantitative trait locus |